Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Gossamer Bio, Inc. | Director | Non-qualified stock option (Right to Buy) | 115K | Jun 6, 2024 | Direct | ||
Magenta Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 20K | Jun 28, 2022 | Direct | ||
Larimar Therapeutics, Inc. | Director | Stock Option (right to buy) | 8.3K | May 12, 2021 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
GOSS | Gossamer Bio, Inc. | Jun 6, 2024 | 1 | $0 | 4 | Jun 6, 2024 | Director |
GOSS | Gossamer Bio, Inc. | Jun 8, 2023 | 1 | $0 | 4 | Jun 9, 2023 | Director |
MGTA | Magenta Therapeutics, Inc. | Jun 28, 2022 | 1 | $0 | 4 | Jun 30, 2022 | Director |
GOSS | Gossamer Bio, Inc. | Jun 9, 2022 | 1 | $0 | 4 | Jul 15, 2022 | Director |
GOSS | Gossamer Bio, Inc. | Jun 9, 2021 | 1 | $0 | 4 | Jun 10, 2021 | Director |
MGTA | Magenta Therapeutics, Inc. | Jun 1, 2021 | 1 | $0 | 4 | Jun 3, 2021 | Director |
LRMR | Larimar Therapeutics, Inc. | May 12, 2021 | 1 | $0 | 4 | May 17, 2021 | Director |